With a one year PEG ratio of 344.67, Sarepta Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.36% of US stocks.
Price to trailing twelve month operating cash flow for SRPT is currently 36.92, higher than 90.51% of US stocks with positive operating cash flow.
With a price/sales ratio of 23.7, Sarepta Therapeutics Inc has a higher such ratio than 93.36% of stocks in our set.
Stocks that are quantitatively similar to SRPT, based on their financial statements, market capitalization, and price volatility, are XLRN, FOLD, BBIO, SGMO, and PTCT.
SRPT's SEC filings can be seen here. And to visit Sarepta Therapeutics Inc's official web site, go to www.sarepta.com.
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.
Sarepta Therapeutics (SRPT) reports that it has received a written response from the FDA's Center for Biologics Evaluation and Research's ((CBER)) Office of Tissues and Advanced Therapies ((OTAT)) concerning its request to use commercial process material for the next clinical trial for SRP-9001, its investigational gene transfer therapy for Duchenne muscular...
Sarepta Therapeutics, Inc. (SRPT) Robert W Baird Global Healthcare Broker Conference Call September 10, 2020, 14:00 ET Company Participants Ian Estepan - SVP, Corporate Affairs & Chief of Staff Douglas Ingram - President, CEO & Director Conference Call Participants Brian Skorney - Robert W. Baird & Co. Presentation Brian Skorney...
SA Transcripts on Seeking Alpha | September 10, 2020
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Sarepta Therapeutics Inc (NASDAQ: SRPT ) is good and he would own it, but he prefers Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ). Cramer would be careful with Lumentum Holdings Inc (NASDAQ: LITE ) because … Full story available on Benzinga.com